FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053188087> ?p ?o ?g. }

• W2053188087 endingPage "415" @default.
• W2053188087 startingPage "406" @default.
• W2053188087 abstract "Purpose Given the promising activity of capecitabine and vinorelbine in metastatic breast cancer, this randomized phase II trial evaluated the efficacy and safety of this combination as neoadjuvant chemotherapy in breast cancer. Materials and Methods Patients with operable breast cancer (n=75) were randomly assigned to receive either four cycles of adriamycin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks followed by four cycles of docetaxel 75 mg/m2 every 3 weeks (AC-D) or four cycles of capecitabine 2,000 mg/m2 (day 1-14) plus vinorelbine 25 mg/m2 (days 1 and 8) every 3 weeks followed by four cycles of docetaxel 75 mg/m2 (CV-D). The primary endpoint was pathologic complete response (pCR) in the primary breast (ypT0/is). Results Most patients (84%) had locally advanced (n=41) or inflammatory breast cancer (n=22). pCR rates in the primary breast were 15% (95% confidence interval [CI], 7% to 30%) and 11% (95% CI, 4% to 26%) in the AC-D and CV-D groups, respectively. The overall response rates and 5-year progression-free survival rates in the AC-D and CV-D groups were 62% and 64%, and 51.3% (95% CI, 34.6% to 68.0%) and 30.2% (95% CI, 13.3% to 47.1%), respectively. Although both regimens were well tolerated, CV-D showed less frequent grade 3-4 neutropenia and vomiting than AC-D, whereas manageable diarrhea and hand-foot syndrome were more common in the CV-D group. Conclusion CV-D is a feasible and active non-anthracycline–based neoadjuvant chemotherapy regimen for breast cancer. Key words: Breast neoplasm, Neoadjuvant therapy, Anthracyclines, Capecitabine, Vinorelbine" @default.
• W2053188087 created "2016-06-24" @default.
• W2053188087 creator A5005381791 @default.
• W2053188087 creator A5007364197 @default.
• W2053188087 creator A5007992707 @default.
• W2053188087 creator A5010518834 @default.
• W2053188087 creator A5016181266 @default.
• W2053188087 creator A5023824632 @default.
• W2053188087 creator A5026459010 @default.
• W2053188087 creator A5031280409 @default.
• W2053188087 creator A5039717324 @default.
• W2053188087 creator A5049348377 @default.
• W2053188087 creator A5075091304 @default.
• W2053188087 creator A5090754319 @default.
• W2053188087 date "2014-11-27" @default.
• W2053188087 modified "2023-10-15" @default.
• W2053188087 title "A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer" @default.
• W2053188087 cites W1919403884 @default.
• W2053188087 cites W1973567302 @default.
• W2053188087 cites W1989644540 @default.
• W2053188087 cites W1991584640 @default.
• W2053188087 cites W2025504439 @default.
• W2053188087 cites W2027544639 @default.
• W2053188087 cites W2029409133 @default.
• W2053188087 cites W2032775660 @default.
• W2053188087 cites W2057084727 @default.
• W2053188087 cites W2075213874 @default.
• W2053188087 cites W2087179076 @default.
• W2053188087 cites W2112894668 @default.
• W2053188087 cites W2114264989 @default.
• W2053188087 cites W2115432999 @default.
• W2053188087 cites W2120639027 @default.
• W2053188087 cites W2127267391 @default.
• W2053188087 cites W2131915049 @default.
• W2053188087 cites W2133764807 @default.
• W2053188087 cites W2135378470 @default.
• W2053188087 cites W2139248078 @default.
• W2053188087 cites W2142245422 @default.
• W2053188087 cites W2153158488 @default.
• W2053188087 cites W2157806784 @default.
• W2053188087 cites W75821465 @default.
• W2053188087 doi "https://doi.org/10.4143/crt.2014.073" @default.
• W2053188087 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4506113" @default.
• W2053188087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25648092" @default.
• W2053188087 hasPublicationYear "2014" @default.
• W2053188087 type Work @default.
• W2053188087 sameAs 2053188087 @default.
• W2053188087 citedByCount "6" @default.
• W2053188087 countsByYear W20531880872016 @default.
• W2053188087 countsByYear W20531880872017 @default.
• W2053188087 countsByYear W20531880872018 @default.
• W2053188087 countsByYear W20531880872021 @default.
• W2053188087 crossrefType "journal-article" @default.
• W2053188087 hasAuthorship W2053188087A5005381791 @default.
• W2053188087 hasAuthorship W2053188087A5007364197 @default.
• W2053188087 hasAuthorship W2053188087A5007992707 @default.
• W2053188087 hasAuthorship W2053188087A5010518834 @default.
• W2053188087 hasAuthorship W2053188087A5016181266 @default.
• W2053188087 hasAuthorship W2053188087A5023824632 @default.
• W2053188087 hasAuthorship W2053188087A5026459010 @default.
• W2053188087 hasAuthorship W2053188087A5031280409 @default.
• W2053188087 hasAuthorship W2053188087A5039717324 @default.
• W2053188087 hasAuthorship W2053188087A5049348377 @default.
• W2053188087 hasAuthorship W2053188087A5075091304 @default.
• W2053188087 hasAuthorship W2053188087A5090754319 @default.
• W2053188087 hasBestOaLocation W20531880871 @default.
• W2053188087 hasConcept C121608353 @default.
• W2053188087 hasConcept C126322002 @default.
• W2053188087 hasConcept C143998085 @default.
• W2053188087 hasConcept C168563851 @default.
• W2053188087 hasConcept C203092338 @default.
• W2053188087 hasConcept C2775930923 @default.
• W2053188087 hasConcept C2776694085 @default.
• W2053188087 hasConcept C2776755627 @default.
• W2053188087 hasConcept C2777063308 @default.
• W2053188087 hasConcept C2777909004 @default.
• W2053188087 hasConcept C2778239845 @default.
• W2053188087 hasConcept C2780350996 @default.
• W2053188087 hasConcept C2781190966 @default.
• W2053188087 hasConcept C526805850 @default.
• W2053188087 hasConcept C530470458 @default.
• W2053188087 hasConcept C71924100 @default.
• W2053188087 hasConcept C90924648 @default.
• W2053188087 hasConceptScore W2053188087C121608353 @default.
• W2053188087 hasConceptScore W2053188087C126322002 @default.
• W2053188087 hasConceptScore W2053188087C143998085 @default.
• W2053188087 hasConceptScore W2053188087C168563851 @default.
• W2053188087 hasConceptScore W2053188087C203092338 @default.
• W2053188087 hasConceptScore W2053188087C2775930923 @default.
• W2053188087 hasConceptScore W2053188087C2776694085 @default.
• W2053188087 hasConceptScore W2053188087C2776755627 @default.
• W2053188087 hasConceptScore W2053188087C2777063308 @default.
• W2053188087 hasConceptScore W2053188087C2777909004 @default.
• W2053188087 hasConceptScore W2053188087C2778239845 @default.
• W2053188087 hasConceptScore W2053188087C2780350996 @default.
• W2053188087 hasConceptScore W2053188087C2781190966 @default.
• W2053188087 hasConceptScore W2053188087C526805850 @default.
• W2053188087 hasConceptScore W2053188087C530470458 @default.

• next